Renal implications of angiotensin receptor blockers

American Journal of Hypertension

Volumn 14, Issue 7 II, 2001, Pages

  Hollenberg, Norman K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin converting enzyme; Angiotensin receptor blocker; Diabetic nephropathy; End stage renal disease; Reninangiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN;

BLOOD PRESSURE REGULATION; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; PLEIOTROPY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0034973463     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(01)02133-1     Document Type: Conference Paper

References (29)

1. Genetics of diabetic nephropathy: Evidence for major and minor gene effects
2. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
3. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
4. Elevation de l'activité de l'enzyme de conversion chez des diabétiques insulino-dépendants présentant une microalbuminurie permanente
5. The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM
6. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity
7. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications
8. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes
9. Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy
10. Association of ACE gene polymorphism and diabetic nephropathy
11. Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension
12. Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans
13. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans
14. Gene polymorphism of the renin-angiotensin system and progression of diabetic nephropathy
15. Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth
16. Molecular biology of the renin-angiotensin system
17. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in noninsulin-dependent diabetes mellitus. A 7-year follow-up study
18. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy
19. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes
20. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
21. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
22. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
23. Impact of angiotensin II on the kidney: Does an angiotensin II receptor blocker make sense?
24. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men
25. Marked species-difference in the vascular angiotensin II-forming pathways: Humans versus rodents
26. Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system
27. Pharmacologic interruption of the renin-angiotensin system and the kidney: Differential responses to angiotensin-converting enzyme and renin inhibition